Owlstone Medical announces investment of up to $2.3 million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detection in cystic fibrosis patients
Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that the Cystic Fibrosis Foundation has made an up to…